Details

Last Funding Type

Series B

Last Funding Money Raised

£22M

Industries

Biotechnology,Health Care,Therapeutics

Founded date

Jan 1, 2006

Number Of Employee

51 - 100

Operating Status

Active

PsiOxus aims to be the world’s leading cancer gene therapy company, delivering medicines of value to patients with cancer.

They focus on discovering and developing innovative gene-based immuno-oncology treatments for solid tumors using their proprietary intravenously administered T-SIGn virus platform. Their portfolio of differentiated gene therapy products are all delivered systemically but act locally within the tumor.

At PsiOxus they are advancing their internal early and clinical stage candidates and establishing strategic partnerships with immuno-oncology leaders to bring their cancer gene therapy products to patients. They focus on discovering and developing innovative gene-based immuno-oncology treatments for solid tumors using their proprietary intravenously administered T-SIGn virus platform. Their portfolio of differentiated gene therapy products are all delivered systemically but act locally within the tumor.